Unknown

Dataset Information

0

GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.


ABSTRACT: Screening of an inhibitor library targeting kinases and epigenetic regulators identified several molecules having antiproliferative synergy with extraterminal domain (BET) bromodomain (BD) inhibitors (JQ1, OTX015) in triple-negative breast cancer (TNBC). GSK2801, an inhibitor of BAZ2A/B BDs, of the imitation switch chromatin remodeling complexes, and BRD9, of the SWI/SNF complex, demonstrated synergy independent of BRD4 control of P-TEFb-mediated pause-release of RNA polymerase II. GSK2801 or RNAi knockdown of BAZ2A/B with JQ1 selectively displaced BRD2 at promoters/enhancers of ETS-regulated genes. Additional displacement of BRD2 from rDNA in the nucleolus coincided with decreased 45S rRNA, revealing a function of BRD2 in regulating RNA polymerase I transcription. In 2D cultures, enhanced displacement of BRD2 from chromatin by combination drug treatment induced senescence. In spheroid cultures, combination treatment induced cleaved caspase-3 and cleaved PARP characteristic of apoptosis in tumor cells. Thus, GSK2801 blocks BRD2-driven transcription in combination with BET inhibitor and induces apoptosis of TNBC. IMPLICATIONS: Synergistic inhibition of BDs encoded in BAZ2A/B, BRD9, and BET proteins induces apoptosis of TNBC by a combinatorial suppression of ribosomal DNA transcription and ETS-regulated genes.

SUBMITTER: Bevill SM 

PROVIDER: S-EPMC6610760 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.

Bevill Samantha M SM   Olivares-Quintero Jose F JF   Sciaky Noah N   Golitz Brian T BT   Singh Darshan D   Beltran Adriana S AS   Rashid Naim U NU   Stuhlmiller Timothy J TJ   Hale Andrew A   Moorman Nathaniel J NJ   Santos Charlene M CM   Angus Steven P SP   Zawistowski Jon S JS   Johnson Gary L GL  

Molecular cancer research : MCR 20190418 7


Screening of an inhibitor library targeting kinases and epigenetic regulators identified several molecules having antiproliferative synergy with extraterminal domain (BET) bromodomain (BD) inhibitors (JQ1, OTX015) in triple-negative breast cancer (TNBC). GSK2801, an inhibitor of BAZ2A/B BDs, of the imitation switch chromatin remodeling complexes, and BRD9, of the SWI/SNF complex, demonstrated synergy independent of BRD4 control of P-TEFb-mediated pause-release of RNA polymerase II. GSK2801 or RN  ...[more]

Similar Datasets

| S-EPMC4854653 | biostudies-literature
| S-EPMC7306005 | biostudies-literature
| S-EPMC5745042 | biostudies-literature
2016-01-07 | E-GEOD-63584 | biostudies-arrayexpress
| S-EPMC7889204 | biostudies-literature
| S-EPMC6886242 | biostudies-literature
2016-01-07 | GSE63584 | GEO
2016-01-07 | E-GEOD-63582 | biostudies-arrayexpress
2016-01-07 | E-GEOD-63581 | biostudies-arrayexpress
2016-01-07 | E-GEOD-63284 | biostudies-arrayexpress